Alerce Investment Management, L.P.

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Alerce Investment Management, L.P. reported 5 stock positions worth $51.0 million. Its top holding was Annexon (ANNX) at 71.1% of the portfolio, followed by Akebia Therapeutics (AKBA, 11.5%) and American Well (6.7%). Compared with Q1 2024, it opened 1 new position, sold out of 1 and reduced 1. The biggest buy was a new position in Verona Pharma (VRNA) and the biggest sale Akebia Therapeutics (AKBA, shares −56%).

Most Recent 13F
Q4 2024
Location
Chicago, IL
CIK
0001844002
Portfolio Value
$51.0M (Q2 2024)
SEC Filing
0000895345-24-000350 ↗ filed Aug 14, 2024

Holdings Value

0$20.0M$40.0M$60.0M$80.0M$100.0M Q1 2024: $95.1M Q1 2024 Q2 2024: $51.0M $51.0M Q2 2024 Q3 2024: $62.3M Q3 2024 Q4 2024: $56.8M Q4 2024

Holdings 5 stocks · $51.0M
ANNX Annexon Inc. 71.13% 7,406,024 $36.3M No change
AKBA Akebia Therapeutics Inc. 11.49% 5,747,906 $5.9M Reduce -56.5%
AMERICAN WELL CORP 6.67% 10,475,717 $3.4M No change
VRNA Verona Pharma Ltd. 6.04% 213,000 $3.1M New
WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC 4.67% 1,630,830 $2.4M No change

Portfolio Sells Q1 2024 → Q2 2024
AKBA Akebia Therapeutics Inc. Reduce -56.5% 11.49% −13.92
RNTX Rein Therapeutics Inc. Sold out 0.00% −5.79

Portfolio Buys Q1 2024 → Q2 2024
VRNA Verona Pharma Ltd. New 6.04% +6.04

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q4 2024 5$56.8MANNX, AKBA, VRNA, AMWL, WHWK
Q3 2024 5$62.3MANNX, AKBA, VRNA, AMWL, WHWK
Q2 2024 5$51.0MANNX, AKBA, AMERICAN WELL CORP, VRNA, WHWK
Q1 2024 5$95.1MANNX, AKBA, AMERICAN WELL CORP, RNTX, WHWK